# ARNA Genomics US Inc.

> ARNA Genomics US Inc. is a San Francisco-based biotechnology company developing multiomics liquid-biopsy technology for early cancer detection. Its lead assay, ARNA Breast, analyzes cell-free DNA and plasma enzyme activity from a routine blood draw to flag early-stage breast cancer, with proof-of-concept studies reporting sensitivity above 90%. Founded in 2013 and led by CEO Egor Melnikov, the company raised a $3.5M Series A in 2020 to fund clinical validation.

- **Founded:** 2013
- **Headquarters:** San Francisco, United States
- **Founders:** Egor Melnikov (Founder & CEO), Anatoliy Melnikov (Co-founder & Chief Scientific Officer), George Nikitin (Co-founder & Chief Technical Officer), Vladimir Savanovich (Co-founder & CIIO), Sergey Dolgachev (Co-founder)
- **Team size:** 7 employees
- **Products:** ARNA Breast, ARNA-1, Multiomics liquid biopsy platform
- **Notable:** Reported 100% sensitivity and 85% specificity for ARNA Breast in a Sechenov University proof-of-concept study, Closed a $3.5M Series A led by Xploration Capital in 2020, Tested more than 600 patients across studies over 9+ years of R&D

## Products & services

- **ARNA Breast** — In vitro diagnostic assay for early-stage breast cancer detection combining oncogene fragment analysis in cell-free DNA with plasma enzyme activity measurement from a blood sample.
- **ARNA-1** — General cancer marker designed to detect oncological disease from blood without prior tumor localization.
- **Multiomics liquid biopsy platform** — Core technology using novel DNA amplification, hybridization and methylation analysis methods to read multiple molecular cancer signals from plasma.

## Achievements

- Reported 100% sensitivity and 85% specificity for ARNA Breast in a Sechenov University proof-of-concept study
- Closed a $3.5M Series A led by Xploration Capital in 2020
- Tested more than 600 patients across studies over 9+ years of R&D
- CEO Egor Melnikov received a CEO Global Award in 2021
- Registered an international multicenter clinical study (NCT04890340) evaluating ARNA Breast against mammography, ultrasound, MRI and biopsy

## Latest updates

- **2021-01** — CEO Egor Melnikov honored with a CEO Global Award.
- **2021-04** — Registered international multicenter clinical study NCT04890340 comparing ARNA Breast to standard imaging and biopsy.
- **2020-09** — Closed $3.5M Series A led by Xploration Capital to fund clinical validation of ARNA Breast.

## Links

- Website: https://arna.bio
- LinkedIn: http://www.linkedin.com/company/arnagenomics
- Twitter/X: https://twitter.com/arnagenomics
- Facebook: https://facebook.com/arnagenomics/

---

Profile page: https://yespress.io/arna-genomics-us-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-13